Health & Science Technologies — Segment Adjusted EBITDA
IDEX Health & Science Technologies — Segment Adjusted EBITDA decreased by 3.6% to $106.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.3%, from $87.40M to $106.00M. Over 4 years (FY 2021 to FY 2025), Health & Science Technologies — Segment Adjusted EBITDA shows an upward trend with a 2.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher values indicate stronger operational performance and profitability within the segment.
Detailed definition
Measures the operational profitability of the Health and Science Technologies segment by adding back depreciation, amort...
Peer comparison
Standard adjusted EBITDA metric used to compare segment performance across diversified industrial and life science companies.
iex_segment_health_science_technologies_segment_adjusted_ebitdaHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $88.98M | $88.98M | $88.98M | $99.80M | $103.60M | $101.40M | $107.00M | $100.70M | $93.70M | $84.40M | $80.70M | $81.40M | $84.20M | $82.60M | $98.60M | $87.40M | $95.00M | $105.40M | $110.00M | $106.00M |
| QoQ Change | — | +0.0% | +0.0% | +12.2% | +3.8% | -2.1% | +5.5% | -5.9% | -7.0% | -9.9% | -4.4% | +0.9% | +3.4% | -1.9% | +19.4% | -11.4% | +8.7% | +10.9% | +4.4% | -3.6% |
| YoY Change | — | — | — | — | +16.4% | +14.0% | +20.3% | +0.9% | -9.6% | -16.8% | -24.6% | -19.2% | -10.1% | -2.1% | +22.2% | +7.4% | +12.8% | +27.6% | +11.6% | +21.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is IDEX's health & science technologies — segment adjusted ebitda?
- IDEX (IEX) reported health & science technologies — segment adjusted ebitda of $106.00M in Q1 2026.
- How has IDEX's health & science technologies — segment adjusted ebitda changed year-over-year?
- IDEX's health & science technologies — segment adjusted ebitda increased by 21.3% year-over-year, from $87.40M to $106.00M.
- What is the long-term trend for IDEX's health & science technologies — segment adjusted ebitda?
- Over 4 years (2021 to 2025), IDEX's health & science technologies — segment adjusted ebitda has grown at a 2.8% compound annual growth rate (CAGR), from $355.90M to $397.80M.
- What does health & science technologies — segment adjusted ebitda mean?
- A measure of the segment's core operational profitability excluding non-cash expenses.